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It is generally accepted that proteases, primarily by degradation of
the cancer-surrounding extracellular matrix, are involved in
tumour cell invasion and metastasis (Reuning et al, 1998). uPA,
tPA, PAI-1, PAI-2 and uPAR are members of the PA proteolytic
system. The PA system controls the conversion of latent plas-
minogen into active plasmin. uPA and tPA activate plasminogen;
PAI-1 and PAI-2 directly inhibit uPA and tPA, thereby indirectly
inhibiting the formation of active plasmin. uPAR is cell
membrane-bound, and by binding its ligand uPA, active plasmin
can be formed in the direct environment of the cell, which
contributes to directional proteolysis.
Clinical studies have shown that levels of PA components in
tumour tissue of various histological types are related to prognosis.
In this regard, breast carcinoma is the most extensively studied
malignancy. By using the enzyme-linked immunosorbent assay
(ELISA) technique, high expression levels of uPA, PAI-1 and
uPAR in tumour extracts have repeatedly been reported to be
related to shorter disease-free interval and overall survival,
whereas high tPA levels were related to a favourable course of
disease. The same trends were found for carcinoma of the
gastrodigestive tract and for various other tumour types (Duffy
et al, 1988; 1999; Ganesh et al, 1996; Andreasen et al, 1997;
Reuning et al, 1998; de Witte et al, 1999).
In addition to ELISA techniques, immunohistochemistry (IHC)
enables assessment of the presence of PA components (Ferrier
et al, 1999). Advantages of IHC are that it can be performed on
routinely processed paraffin-embedded tissues (Ferrier et al,
1998a; Ruiter et al, 1998a), and that it gives insight into the distri-
bution of the proteins over different cell types and different areas
of the tumour. By IHC, the adverse prognostic value of high uPA,
PAI-1 and uPAR expression and the favourable prognostic value
of high PAI-2 expression has been shown for breast cancer (Kim
et al, 1997; Umeda et al, 1997), cervical cancer of the uterus
(Kobayashi et al, 1994), epithelial ovarian cancer (Chambers et al,
1997; 1998), pancreatic cancer (Takeuchi et al, 1993), oesophagus
cancer (Torzewski et al, 1997), gastric cancer (Ito et al, 1996;
Allgayer et al, 1998), colorectal cancer (Mulcahy et al, 1994; Sato
et al, 1995; Berney et al, 1998; Kim et al, 1998b), upper urinary
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tract carcinoma (Nakanishi et al, 1998) and glioma (Hsu et al,
1995). However, in non-small cell lung cancer, neither ELISA nor
IHC determinations for PAI-1 and uPAR were related to survival
(Pappot et al, 1997).
Observations in experimental systems and on clinical material
also pointed to a role for proteases in melanocytic tumour progres-
sion (see reviews by de Vries et al, 1996; Mueller, 1996; Ferrier
et al, 1998b). The presence of PA components in common naevi,
dysplastic naevi and malignant melanoma has earlier been studied
by us (de Vries et al, 1994) and others (Delbaldo et al, 1994) using
IHC, in situ hybridization and in situ zymography. Both found an
increase of expression with higher grade of disease, and concluded
that components of the PA system are markers for progression in
melanocytic lesions. Also in uveal melanoma, high uPA expres-
sion was shown to be associated with progression of disease
(de Vries et al, 1995).
In the present study we investigated the potential of uPA, tPA,
PAI-1, PAI-2 and uPAR expression to be markers for prognosis in
primary melanoma. Therefore, IHC staining was performed on
214 primary cutaneous melanomas from clinical stage II
(T3–4N0M0, American Joint Committee on Cancer) patients with
well documented follow-up. Expression levels were correlated to:
Table 1 Patient characteristics and outcome of disease
Overall group Subgroups of tPA tumour cell positivitya
0–5% 6–50% 51–100%
n = 214 (%) n = 166 (%) n = 26 (%) n = 21 (%)
Age at registration (yrs)
Median 50 50 54 45
Range 17–73 17–73 36–71 25–70
≤45 86 (40.2) 68 (41.0) 6 (23.1) 11 (52.4)
46–60 78 (36.4) 59 (35.5) 13 (50.0) 6 (28.6)
³61 50 (23.4) 39 (23.5) 7 (26.9) 4 (19.0)
Sex
Female 147 (68.7) 115 (69.3) 17 (65.4) 14 (66.7)
Male 67 (31.3) 51 (30.7) 9 (34.6) 7 (33.3)
Site
Upper limb 58 (27.1) 44 (26.5) 8 (30.8) 6 (28.6)
Lower limb 156 (72.9) 122 (73.5) 18 (69.2) 15 (71.4)
Treatment
Wide excision (WE) 110 (51.4) 85 (51.2) 11 (42.3) 13 (61.9)
WE plus limb perfusion 104 (48.6) 81 (48.8) 15 (57.7) 8 (38.1)
Elective lymph-node dissection
No 156 (72.9) 122 (73.5) 19 (73.1) 14 (66.7)
Yes 57 (26.6) 43 (25.9) 7 (26.9) 7 (33.3)
Unclassified 1 (0.5) 1 (0.6) 0 0
Breslow thickness
≤2 mm 44 (20.5) 35 (21.1) 4 (15.4) 4 (19.0)
>2 mm and ≤4 mm 114 (53.3) 92 (55.4) 13 (50.0) 9 (42.9)
>4 mm 56 (26.2) 39 (23.5) 9 (34.6) 8 (38.1)
Clark’s invasion level
3 58 (27.1) 46 (27.7) 5 (19.2) 6 (28.6)
4 138 (64.5) 105 (63.3) 19 (73.1) 14 (66.7)
5 18 (8.4) 15 (9.0) 2 (7.7) 1 (4.7)
Histological subtype
Superficial spreading 93 (43.5) 78 (47.0) 8 (30.8) 7 (33.3)
Nodular 86 (40.2) 59 (35.5) 14 (53.9) 12 (57.2)
Acro-lentiginous 27 (12.6) 22 (13.3) 3 (11.5) 2 (9.5)
Unclassified 8 (3.7) 7 (4.2) 1 (3.8) 0
Microscopic ulceration
Absent 128 (59.8) 99 (59.6) 13 (50.0) 16 (76.2)
Present 85 (39.7) 66 (38.8) 13 (50.0) 5 (23.8)
Unclassified 1 (0.5) 1 (0.6) 0 0
Clinical course
Recurrence (local, regional or systemic)
No 131 (61.2) 104 (62.7) 11 (42.3) 16 (76.2)
Yes 83 (38.8) 62 (37.3) 15 (57.7) 5 (23.8)
Distant metastasis
No 162 (75.7) 127 (76.5) 14 (53.8) 20 (95.2)
Yes 52 (24.3) 39 (23.5) 12 (46.2) 1 (4.8)
Survival status
Alive 161 (75.2) 127 (76.5) 14 (53.8) 19 (90.5)
Deadb 53 (24.8) 39 (23.5) 12 (46.2) 2 (9.5)
aOne tPA score was missing for a young female with a nodular melanoma on the leg, Breslow thickness ≤2 mm, Clark level 3, ulceration present, treated by
wide excision, no elective lymph-node dissection. Follow-up revealed a recurrence, no distant metastasis or death. bDeath cases were melanoma-related with
the presence of distant metastasis in 49 cases, melanoma-independent with the presence of a distant metastasis in one case, melanoma-independent without
the presence of distant metastasis in two cases and without known cause in one caseSerine protease system in melanoma 1353
British Journal of Cancer (2000) 83(10), 1351–1359 © 2000 Cancer Research Campaign
disease-free interval; time to distant metastases; and overall
survival. The additive value in relation to established prognostic
factors was evaluated by multivariate analysis.
PATIENTS, MATERIALS AND METHODS
Patients
Two hundred and fourteen clinically stage II (T3–4N0M0, American
Joint Committee on Cancer) patients with primary melanoma of
the limb were evaluated. These patients were enrolled in an inter-
national phase III trial (no. 18832, by the European Organization
for Research and Treatment of Cancer), testing the benefits of
wide excision of the primary lesion plus prophylactic isolated limb
perfusion with melphalan under mild hyperthermia as compared to
wide excision only (Schraffordt Koops et al, 1998). Relevant
inclusion criteria were tumour localization at or distal to the
middle of the thigh or upper arm and a tumour-thickness of mini-
mally 1.5 mm (T3–4) as measured by the local pathologist. In spite
of the tumour thickness requirement, three lesions had a Breslow
thickness below 1.5 mm, due to discrepancies between Breslow
indices as measured by the first pathologist and the reviewing
pathologist. Patients who had (excision) biopsy of the primary
melanoma more than 6 weeks before were not eligible for partici-
pation in the trial. For the present study, Dutch participants,
included between 1986 and 1993, were studied. Complete 
follow-up was available for all patients. For detailed patient
characteristics, see Table 1.
Tissues
Paraffin blocks were collected from 45 different departments of
pathology. All tissues had been routinely processed. Of each
primary melanoma, the tissue block containing the thickest portion
of the lesion was selected for investigation.
Immunohistochemistry
Of each lesion 4 mm thick sections were stained with polyclonal
antibodies against uPA (rabbit antibody, DAKO, Glostrup,
Denmark), tPA (goat antibody no. 387, American Diagnostica,
Greenwich CT, USA), PAI-1 (rabbit antibody, Department of
Experimental and Chemical Endocrinology, University Medical
Center St Radboud, Nijmegen, The Netherlands (Grebenschikov
et al, 1997)), PAI-2 (goat antibody, Behring Werke AG, Marburg,
Germany) and uPAR (rabbit antibody, Finsen Laboratory,
Copenhagen, Denmark (Rønne et al, 1995)). To check sensitivity
and specificity, stainings with other antibodies against tPA (rabbit
polyclonal antibody, Department of Experimental and Chemical
Endocrinology, University Medical Center St Radboud, Nijmegen,
The Netherlands (Grebenschikov et al, 1997)), PAI-2 (goat poly-
clonal antibody, Institute for Immunology, University Hospital
Heidelberg, Germany (Schaefer et al, 1996)) and uPAR (mono-
clonal antibody R2, Finsen Laboratory (Rønne et al, 1991)), and
with two other antibodies against PAI-1 (monoclonal antibody
Clone 1, Monozyme, Hoersholm, Denmark; monoclonal antibody
no. 380, American Diagnostica) were compared on more than 100
lesions.
IHC procedures were performed as described previously
(Ferrier et al, 1998a). In brief, firstly the epitopes for antibody
recognition were retrieved by microwave-heating (for tPA, PAI-1
and PAI-2) or by protease digestion (for uPA and uPAR). Then, the
sections were stained by a three-step procedure using biotinylated
secondary antibodies in combination with alkaline phosphatase-
labelled avidin–biotin complex (Vector Laboratories, Burlingame
CA, USA). Secondary antibodies were goat anti-rabbit immunog-
lobulin (Vector Laboratories), donkey anti-mouse immunoglobulin
(Jackson, West Grove PA, USA), and donkey anti-goat im-
munoglobulin (Jackson). Vector Red (Vector Laboratories) was
used as substrate to enable a clear distinction between melanin
granules and staining signal.
For each component, positive and negative tissue controls
(Ferrier et al, 1998a), plus cancer lesions known to contain both
antigen-positive and antigen-negative areas were included in each
staining session. Negative staining controls were performed on a
subset of antigen-positive primary melanoma lesions by replacing
monoclonal antibodies with an isotype-matched irrelevant anti-
body (DAKGO1, Dako) and by replacing polyclonal antibodies
with a primary antibody dilution which was affinity-absorbed with
purified antigen and by ommission of the first antibody.
Scoring
Sections stained with polyclonal antibodies that had been used
on the total group of 214 lesions were scored. First, to advance
standardization, scores were assessed by joint judgement (CMF,
GNPvM and DJR). After these sessions, sections were primarily
scored by one observer (CMF), with joint scoring sessions for
20–30% of the sections, including random cases and all cases
difficult to score. Melanoma cells were scored according to the
percentage of positive cells in six categories: 0–1%, 2–5%,
6–25%, 26–50%, 51–75% or 76–100%. The distribution of
melanoma cell staining was judged as: diffuse positivity, involving
large continuous parts of the tumour; scattered positivity of single
cells; or focal positivity of clusters of cells. In case of focal posi-
tivity, the involvement of junctional/subepidermal, central and/or
frontal nests was noted. For stromal staining, the type of positive
cells (fibroblast-like cells, macrophages, endothelial cells) was
recorded and an estimate of the quantity of positive cells was made
(0 = nil; 1 = a few cells; 2 = several clusters of cells; 3 = abundant
stromal-cell positivity). Only stainings exceeding weak intensity
were considered as positive.
Statistical methods
For statistical evaluation, percentage-classes reflecting the extent
of tumour cell positivity were taken together to form the categories
0–5%, 6–50% and 51–100% positive tumour cells.
Associations between the extent of tumour cell positivity of
different components with each other were assessed by the
Spearman’s rank correlation coefficient. Relation between on the
one side percentage categories (0–5%, 6–50% and 51–100%) and
staining patterns of the investigated components, and on the other
side established prognostic variables such as Breslow thickness,
ulceration and sex, were determined by Spearman’s rank correla-
tion and/or Kruskall–Wallis test.
Starting point for the different analyses was the date of registra-
tion in clinical trial no. 18832. The end-point for relapse-free
interval was the date of first progression, whether local relapse, in-
transit metastasis, regional lymph-node metastasis or distant
metastasis. The end-point for distant metastasis-free interval was
the diagnosis of distant metastasis. The end-point for the duration1354 CM Ferrier et al
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of survival was the date of death, whatever cause. Patients still
alive were considered as censored observations at the date of last
follow-up. The prognostic impact of a given variable, like sex, age,
site of primary melanoma, Breslow thickness, ulceration, Clark’s
level of invasion, type of melanoma, treatment randomized, elec-
tive lymph-node dissection, variables resulting from the IHC stain-
ings, was first analysed univariately by estimation of the relative
risks of having an event (recurrence of disease, distant metastasis,
death) per unit time, along with its 95% confidence interval by
applying the Cox proportional hazards method (Cox, 1972).
P values were calculated by the –2log likelihood test. For tPA, in
addition, survival curves were computed using the Kaplan–Meier
technique (Kaplan and Meier, 1958). Differences between curves
were tested using the log-rank test. Subsequently, independence of
prognostic factors was assessed. Therefore, each variable univari-
ately reaching significance (P ≤ 0.05) for one of the end-points
was studied in a multivariate Cox proportional hazards model.
RESULTS
Staining results
Staining results obtained by different antibodies against tPA, PAI-1,
PAI-2 and uPAR yielded concordant patterns per component with
slight variations in intensities. Frequency distributions of the
extent of tumour cell staining and of the staining patterns are
summarized in Figures 1 and 2. PAI-1 showed a particular staining
pattern; focal staining with participation of junctional/subepi-
dermal tumour nests was seen in the majority of positive cases.
103 of 118 PAI-1-positive lesions had focal tumour cell staining;
the junctional/subepidermal region was involved in 100 cases,
central tumour parts in 33 cases and the frontal region in 17 cases.
For tPA, because of its relation to outcome of disease (see
univariate and multivariate analyses), frequencies of the extent of
tumour cell positivity are depicted for patient and treatment vari-
ables (Table 1). Representative IHC staining results are shown in
Figure 3.
Spearman’s rank correlation coefficients between the extent of
tumour cell expression of the different components were weak,
although significant between uPAR on the one side and uPA, tPA
and PAI-2 on the other side (r = 0.21, 0.17 and 0.16, respectively),
and between PAI-2 and tPA (r = 0.34).
Stromal cell staining of macrophages, fibroblast-like cells and
endothelial cells was usually very limited; only for PAI-2 and
uPAR did more than 10 lesions have stromal cell positivity which
exceeded a few cells.
Correlation of new variables with established
prognostic clinicopathological variables
The percentage of PAI-1-positive tumour cells was negatively
correlated with Breslow thickness (Spearman’s rank correlation
coefficient = –0.18, P = 0.009). Other significant correlations with
Breslow thickness, sex or ulceration were not found, neither for
the percentage of positive cells nor for staining pattern.
Prognostic factor analyses
Established prognostic factors
As shown in Table 2, Breslow thickness and microscopic ulcera-
tion were important prognostic factors for each of the end-points
time to recurrence of disease, time to distant metastasis and overall
survival. Sex, site and randomized treatment appeared to be signi-
ficant for one of these endpoints; subtype, Clark’s level, age and
elective lymph-node dissection did not reach the significance level
in any analysis.
uPA, PAI-1, PAI-2, uPAR
Regarding disease-free interval, time to distant metastasis and
survival, Cox proportional hazards analysis did not yield significant
risk ratios for either percentage of positive tumour cells or the pattern
of tumour cell positivity. For PAI-2 and uPAR, the extent of stromal
cell positivity was statistically evaluated, since for these components
more than ten lesions had substantial stromal cell positivity.
However, no groups with differences in prognosis were found.
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tPA
Figure 4 shows the prognostic impact of tPA on the three end-
points relapse-free interval, distant metastasis-free interval and
duration of survival. In each of these analyses, patients with
lesions having tumour cell positivity in the intermediate category
(6–50%) had the worst prognosis, whereas those with the highest
percentage of positivity (51–100%) had the best outcome. Table 2
shows the estimated relative risks along with the confidence inter-
vals corresponding to these two groups of patients as compared
with the one with the lowest degree of positivity (0–5%). The Cox
proportional hazards model showed that if other factors, like
Breslow thickness, ulceration, sex, site and allocated treatment, are
taken into consideration, the degree of tPA-positivity remained of
prognostic importance for the time to distant metastasis (P =
0.012) and for the duration of survival (P = 0.043). In these two
analyses, the relative risk estimates of the middle group (6–50%
positivity) compared with the 0–5% group equalled 1.9 and the
relative risk estimates of the highest group (51–100% positivity)
AB
CD E
E
E
E
FG
Figure 3 Primary melanoma lesions stained for tPA (A, B), uPA (C), PAI-2 (D), PAI-1 (E), and uPAR (F, G). (A) Lesion with complete tPA tumour cell positivity.
(B) Strong tPA-positive tumour nests and adjacent weakly-positive tumour nests. (C) Strong uPA-positivity of tumour nests from the horizontal growth phase
(asterisks), and weak positivity of the epidermis (E). (D) Strong PAI-2-positivity of the epidermis and epidermal extensions (E) and negativity of melanoma cells.
(E) PAI-1 positivity of subepidermal melanoma nests, a staining pattern frequently encountered for PAI-1. (F) A lesion with diffuse uPAR-positivity of tumour
nests and of stromal cells surrounding these nests. (G) Lesion with uPAR-staining of frontally located stromal cells. Only a very limited number of tumour cells
are positive1356 CM Ferrier et al
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awere 0.2 and 0.4 respectively. When another approach was chosen,
including in the multivariate model only those variables that were
significant in univariate analysis for that specific end-point, the
relative risks for tPA-positivity changed slightly. Furthermore, the
corresponding P-values decreased, which emphasized even more
the prognostic importance of tPA-positivity (results not shown).
DISCUSSION
Former studies on frozen sections of melanomas found compo-
nents of the PA system to be associated with melanoma progres-
sion (Delbaldo et al, 1994; de Vries et al, 1994). This stimulated us
to perform the present study based on primary melanomas of the
limb from patients who had been prospectively followed in the
framework of an EORTC trial (no. 18832). To that end, 214
routinely processed paraffin-embedded primary melanoma lesions
were IHC stained.
Differences in uPA, tPA, PAI-1 and PAI-2 expression patterns
between former studies (Delbaldo et al, 1994; de Vries et al, 1994)
and the present study may be explained by the relatively small
number of advanced primary melanomas investigated in the
previous studies, which makes results less suitable for generaliza-
tion. Moreover, the former studies were performed on frozen tissue
samples, which are mostly of limited volume, but which have
better antigen preservation. Since especially uPA was previously
found to be sensitive to fixation time (Ferrier et al, 1998a), this
should be kept in mind considering the low percentage of uPA-
positive lesions found in the present study. For PAI-1, we found in
an earlier study that this antigen on stromal cells cannot be as reli-
ably unmasked as on tumour cells (Ferrier et al, 1998a).
Remarkably, extensive tPA-expression of melanoma cells was
related to favourable outcome, whereas for none of the compo-
nents expression was related to unfavourable outcome of disease,
stressing the point that a progression marker is not automatically a
prognostic parameter for aggressiveness of disease (Ruiter and van
Muijen, 1998b).
The present study showed best prognosis for the group with
abundant tPA tumour cell positivity (51–100%), worse outcome
for the limited tPA tumour cell positive group (0–5%), and, strik-
ingly, worst outcome in patients with intermediate tPA tumour cell
expression (6–50%). No relation between staining pattern and
course of disease was found. tPA tumour cell positivity was an
independant prognostic factor for distant metastasis-free interval
and overall survival in a multivariate model including other prog-
nostic parameters like Breslow thickness, ulceration, sex, site and
treatment.
Attempting to exclude the possibility of a statistical artefact,
analyses for tPA were repeated in another small (n = 24) group of
European patients that were enrolled in another EORTC trial (no.
18871). This limited study confirmed the results described in this
work (results not shown).
The fact that high tPA correlates with good prognosis is not
unexpected. This correlation was also found for other types of
tumour (Duffy et al, 1998; Jänicke et al, 1991; Yamashita et al,
1993; 1995; Bindal et al, 1994; Ganesh et al, 1996; Duggan et al,
1997; Ruppert et al, 1997; Kim et al, 1998a; de Witte et al, 1999),
mostly by using the ELISA technique. Regarding the role of tPA in
melanoma invasion, in vitro experiments and animal experimental
observations have shown equivocal results (for reviews see de
Vries et al, 1996; Ferrier et al, 1998b).
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Figure 4 Kaplan–Meier curves for recurrence-free interval. (A), distant
metastasis-free interval (B) and overall survival (C). P-values were calculated
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Host protective effects of tPA may be caused by dissolution of
the fibrin coating of tumour emboli, as previously discussed by
Yamashita et al (1993). Tumour cell-generated thrombin causes
intravascular tumour cells to form microthrombi consisting of
tumour cells, platelets and fibrin. These microthrombi secure the
arrest of cancer cells in the capillaries and may lead to diapedesis
through the capillary wall into the tissues (Rickles and Edwards,
1983; Markus, 1984; Francis et al, 1998; Engelberg, 1999). Fibrin
coating is found to protect tumour cells against the lytic effects of
natural killer cells and lymphokine-activated killer cells (Gunji
and Gorelik, 1988; Cardinali et al, 1990). Fibrinolysis by circu-
lating tumour cells, for example by means of fibrin-activated tPA,
with consequent dissolution of fibrin deposits around embolized
peripheral tumour cells, may decrease the chances of these cells to
implant and to form metastases. Another host-protective effect
may be the formation of angiostatin, a tumour-derived angiogen-
esis inhibitor (O’Reilly et al, 1996). A recent study of our group
revealed that angiostatin formation by human melanoma cell lines
is basically tPA-dependent (Westphal et al, 2000).
A tumour metastasis-promoting effect of tPA may be plasmin-
mediated degradation of extracellular matrix. This may facilitate
local invasion and release of tumour cells into the circulation.
However, several experimental reports indicate that melanoma
progression appears to be uPA rather than tPA-related (Quax et al,
1991; Meissauer et al, 1992; Huijzer et al, 1995; Shapiro et al,
1996). A possible stimulatory effect of tPA on angiogenesis might
also enhance metastatic potential (Sato et al, 1993; Hu et al, 1994;
Welling et al, 1996), although no influence of tPA on angiogenesis
was found by others (Takei et al, 1995; Lansink et al, 1998;
Sakamoto et al, 1998).
Based on the foregoing, it may be speculated that a shifting
balance of metastatic and anti-metastatic effects may act simulta-
neously with a different predominant effect depending on the level
of tPA. A more or less comparable finding was reported by
Yamashita et al (1993), who found that a breast cancer group that
remained distant metastasis-free had highest tPA-antigen levels
and tPA-activity. Most seriously diseased patients (lung or both
lung and bone metastases) had intermediate levels and the group
with only bone metastases (bone metastases were explained to
often remain localized in the bone for a long time without any
further evidence of metastases) had lowest levels.
The apparently complex association between tPA-expression
and the outcome of disease in case of melanoma needs to be vali-
dated in further series. If the present results are confirmed, it may
be considered to offer adjuvant therapy to patients with tPA-based
unfavourable prognosis, whereas for patients with high tPA-
expressions, and therefore favourable prospects, no additional
therapy would be indicated.
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